Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...

DiveWire guarantees visibility for your news announcements through instant distribution to Restaurant Dive’s audience and its 42,500 newsletter subscribers for 21 days.

Articles, multimedia, and data visualizations by Pulitzer Center grantees from around the world.